Neurotheranostics as personalized medicines

Bhavesh D. Kevadiya, Brendan M. Ottemann, Midhun Ben Thomas, Insiya Mukadam, Saumya Nigam, Jo Ellyn McMillan, Santhi Gorantla, Tatiana K. Bronich, Benson Edagwa, Howard E. Gendelman

Research output: Contribution to journalReview articlepeer-review

56 Scopus citations


The discipline of neurotheranostics was forged to improve diagnostic and therapeutic clinical outcomes for neurological disorders. Research was facilitated, in largest measure, by the creation of pharmacologically effective multimodal pharmaceutical formulations. Deployment of neurotheranostic agents could revolutionize staging and improve nervous system disease therapeutic outcomes. However, obstacles in formulation design, drug loading and payload delivery still remain. These will certainly be aided by multidisciplinary basic research and clinical teams with pharmacology, nanotechnology, neuroscience and pharmaceutic expertise. When successful the end results will provide “optimal” therapeutic delivery platforms. The current report reviews an extensive body of knowledge of the natural history, epidemiology, pathogenesis and therapeutics of neurologic disease with an eye on how, when and under what circumstances neurotheranostics will soon be used as personalized medicines for a broad range of neurodegenerative, neuroinflammatory and neuroinfectious diseases.

Original languageEnglish (US)
Pages (from-to)252-289
Number of pages38
JournalAdvanced Drug Delivery Reviews
StatePublished - Aug 2019


  • Alzheimer's disease (AD)
  • Blood brain barrier (BBB)
  • Brain-targeted nanoparticles
  • Magnetic resonance imaging (MRI)
  • Nanomedicine
  • Neurodegenerative disorders
  • Neuroimaging
  • Neurotheranostics
  • Parkinson's disease (PD)
  • Single photon emission computed tomography (SPECT/CT)
  • Theranostics

ASJC Scopus subject areas

  • Pharmaceutical Science


Dive into the research topics of 'Neurotheranostics as personalized medicines'. Together they form a unique fingerprint.

Cite this